Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of TX103 CAR-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma.

NCT06482905 is registered in ClinicalTrials.gov with Tcelltech Inc. as lead sponsor.

NCT NCT06482905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06482905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of TX103 CAR-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma.
Lead sponsor
Tcelltech Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 4, 2024
Completion date
June 30, 2027
Enrollment
52 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma, who grade Ⅳ glioma